Distribution of current prognostic factors in long-term surviving glioblastoma patients. A single center retrospective analysis

Genevieve Schindler, David Capper, Kirsten Schmieder & Christopher Brenke
Objective: Despite improved treatment regimes for Glioblastoma patients, the median overall survival (OS) remains poor at 12–15 months. Over the last decade molecular and therapeutic prognostic factors have been described. The clinical implication of these factors is subject of ongoing trials.[for full text, please go to the a.m. URL]